Citryll

Executive Summary

Citryll is a Netherlands-based biotechnology company developing first-in-class monoclonal antibodies targeting Neutrophil Extracellular Traps (NETs) for immune-mediated inflammatory diseases. Its lead asset, CIT-013, aims to inhibit NET formation and enhance clearance, addressing a novel pathway in chronic inflammation. The company is currently in Phase 2 clinical development, with potential to address significant unmet need in diseases such as rheumatoid arthritis and lupus. Citryll's approach differentiates from standard anti-inflammatory therapies by targeting the root cause of NET-driven pathology.

Upcoming Catalysts (preview)

• H2 2026Phase 2 top-line data readout for CIT-01350% success
• 2026Strategic partnership or licensing deal40% success
• 2026Series B or other financing round70% success